Impact of Implementation of the High-Sensitivity Cardiac Troponin T Assay in a University Hospital Setting

To the Editor:
The performance of the highsensitivity cardiac troponin T assay (hs-cTnT) 1 has been evaluated in a multicenter study (1 ) . Effective July 2009, we replaced the fourth-generation troponin T assay (cTnT) with the hs-cTnT assay in clinical practice. This study audits the impact of this implementation.
The hs-cTnT, implemented on the cobas e 411 platform (Roche Diagnostics), fully replaced the cTnT performed on the Elecsys 2010 analyzer [cutoff, 30 pg/mLbased on actual assay performance (10% CV concentration)]. We obtained a detection limit of 5 pg/mL, a 99th percentile of 15 pg/mL, limited comparability with the cTnT at concentrations Ͻ100 pg/mL (on average, a 30-pg/mL cTnT concentration yielded a value of approximately 65 pg/mL with the hscTnT) and mean CVs of 9.1% for the cTnT (at 39 pg/mL) and 8.5% for the hs-cTnT (at 17 pg/mL). We retrieved hs-cTnT results for the first 3 months after implementation (July 16 to October 15, 2009) and cTnT results for the same period 1 year previously. Results were dichotomized as positive or negative with respect to cutoffs. Among troponin-positive patients with at least 2 results during their examination, we divided markerrelease curves on the basis of typical or atypical kinetics. We defined as "typical" an increasing or decreasing pattern showing a troponin change between 2 consecutive samples exceeding ϩ46% for increasing troponin results and Ϫ32% for decreasing results. Otherwise, the troponin pattern was considered "atypical." For definition of these percentage changes, we referred to the shortterm biological variation for troponin I (2 ). We are aware, however, that the 2 cardiac troponins may have different biological kinetics in blood, so their biological variation may be different.
In the evaluated period, 2287 hs-cTnT tests were performed during 1371 examinations of 1137 patients. Correspondingly, 2170 cTnT tests were performed during 1409 examinations of 1205 patients. After hs-cTnT implementation, a 5.4% increase in the hospital-wide test volume was recorded, despite a slight decrease in the number of admitted patients and examinations. The mean (SD) number of troponin tests per examination was 1.54 (1.0) before and 1.67 (1.1) after hs-cTnT implementation (P Ͻ 0.0001), with a single test ordered in 67.5% and 60.2% of examinations, respectively. The distribution of troponin orders and positive-test rates in different wards is shown in Table 1 . A positive result was found in 31.7% of cTnT tests and in 58.7% of hs-cTnT tests (relative difference, ϩ85%), corresponding to 25.3% and 51.6% positive examinations, respectively (P Ͻ 0.0001). Of all the hs-cTnT positive results, 64% fell in the 16 -65 pg/mL interval, previously negative with the cTnT. In the emergency department after hs-cTnT implementation, the number of hospitalized patients with positive troponin results increased from 158 to 292 (ϩ85%), but the rate of admission in intensive care and nonintensive care departments was unchanged (P ϭ 0.108). In the same periods, 16 cTnT-positive patients (8.5%) and 109 hscTnT-positive patients (26.6%) were discharged. Of these discharged patients, 1 cTnT-positive patient and 13 hs-cTnT-positive patients were readmitted to the emergency department in the subsequent 2 months (P ϭ 0.804, between the 2 assays).
We audited 458 cTnT and 546 hs-cTnT curves, of which 39.1% and 69.0%, respectively, had at least 1 positive result (P Ͻ 0.0001). The difference in the percentage of positive curves displaying a typical marker release was not significant (17.2% for the cTnT vs 20.5% for the hs-cTnT, P ϭ 0.32). A higher absolute number of typical positive curves was observed after hscTnT implementation (from 79 to 112). This increased ability to detect events involving acute marker release was fully explained by the number of typically positive curves in which the hs-cTnT result never exceeded 65 pg/mL (n ϭ 38).
The replacement of the cTnT with the hs-cTnT markedly increased the rate of positive tests. A similar outcome was previously described for a contemporary sensitive troponin I assay (3 ) . What is unique in our experience is the magnitude of the increase in positive results after hs-cTnT introduction, which was based on imple-menting this assay in a routine protocol. The number of examinations with positive results increased from approximately 25% to Ͼ50%. Although the hs-cTnT could appear confounding as a test less specific for the diagnosis of myocardial infarction (4 ), we were unable to demonstrate differences in the percentage of curves with a typical marker release when we compared the cTnT and the hs-cTnT. An interpretative approach based on the demonstration of a pathophysiology-defined release of troponin in the blood may allow the same specificity performance to be achieved when using different generations of troponin T assays, thus supporting the use of serial testing for clinical decisions (5 ). 
Letters to the Editor
